lymphocytic leukemia is expected to be started in the United States by
Micromet's collaboration partner MedImmune. In addition, at the
conference of the American Society of Hematology (ASH) in December 2008,
Micromet anticipates that it will provide an update on the clinical
data of the ongoing clinical trials with MT103.
-- Micromet expects to initiate dosing of patients in a phase 1 clinical
trial of MT110 in patients with solid tumors in the first half of 2008.
-- Micromet is currently developing the study design for a clinical trial
to evaluate adecatumumab (MT201) in an adjuvant setting and plans to
initiate this clinical trial in the second half of 2008. In addition,
data of the ongoing phase 1b combination trial with docetaxel are
expected to be presented in the second half of 2008.
-- Micromet expects to initiate IND-enabling studies with MT203 as part of
its collaboration with Nycomed.
Conference Call and Audio Webcast Today, March 13, 2007, at 9:00am Eastern Time
To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website.
A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.
About Micromet, Inc. (http://www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation and
autoimmune diseases. Three of its antibodies are currently in clinical
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved